{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:33:18Z","timestamp":1772447598595,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,3,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Clinical data are lacking concerning concomitant administration of everolimus and tacrolimus in renal transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>In a prospective, multicenter, open-label, exploratory, randomized, 6-month study, 92 de novo renal transplant patients received everolimus, steroids, and basiliximab with low or standard tacrolimus exposure. The primary objective was to compare renal function at 6 months after transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Mean 6-month serum creatinine (primary safety variable) was 112\u00b131 \u03bcmol\/L (1.26\u00b10.35 mg\/dL) and 127\u00b150 \u03bcmol\/L (1.44\u00b10.57 mg\/dL) in the low and standard tacrolimus groups, respectively, (n.s.); mean estimated GFR (Nankivell) was 75.3\u00b116.6 mL\/min and 72.5\u00b115.2 mL\/min (n.s.). Biopsy-proven acute rejection occurred in 13 patients: seven (14%) in the low tacrolimus group and six (14%) in the standard tacrolimus group, n.s. One graft was lost in the standard tacrolimus group. No patients died.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Tacrolimus exposure reduction in the presence of everolimus, steroids and basiliximab induction results in good efficacy in de novo renal transplant recipients with very well-preserved renal function. Additional studies are warranted because between-group comparisons were limited by the relatively small differences in tacrolimus exposure in the 2 arms; trough levels were toward the upper end of the low-exposure ranges and toward the bottom of the standard-exposure ranges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0b013e318166927b","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T19:36:47Z","timestamp":1236109007000},"page":"821-826","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":92,"title":["Multicenter, Randomized Study of the Use of Everolimus With Tacrolimus After Renal Transplantation Demonstrates its Effectiveness"],"prefix":"10.1097","volume":"85","author":[{"given":"Laurence","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Greenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suphamai","family":"Bunnapradist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Cibrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Munir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Ulbricht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20260130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, A new rapamycin derivative. Pharmacologic properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"R2-7-20260130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199512000-00019","article-title":"Rapamune (Sirolimus, rapamycin): An overview and mechanism of action","volume":"17","author":"Sehgal","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R3-7-20260130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"R4-7-20260130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, Phase III, randomized, controlled safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"R5-7-20260130","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","article-title":"Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combinations","volume":"12","author":"Podder","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R6-7-20260130","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year Phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"R7-7-20260130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"R8-7-20260130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year","volume":"80","author":"Mendez","year":"2005","journal-title":"Transplantation"},{"key":"R9-7-20260130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.tp.0000203894.53714.27","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimums\/mycophenolate versus cyclosporine\/sirolimus in renal transplantation: Three-year analysis","volume":"81","author":"Ciancio","year":"2006","journal-title":"Transplantation"},{"key":"R10-7-20260130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1600-6143.2006.01340.x","article-title":"Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF","volume":"6","author":"Gallon","year":"2006","journal-title":"Am J Transplant"},{"key":"R11-7-20260130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-6143.2005.01193.x","article-title":"Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study","volume":"6","author":"Vitko","year":"2006","journal-title":"Am J Transplant"},{"key":"R12-7-20260130","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/j.1600-6143.2005.01019.x","article-title":"Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus","volume":"5","author":"Meier-Kriesche","year":"2005","journal-title":"Am J Transplant"},{"key":"R13-7-20260130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":"The Banff 97 working classification of renal allograft pathology","volume":"55","author":"Racusen","year":"1999","journal-title":"Kidney Int"},{"key":"R14-7-20260130","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"},{"key":"R15-7-20260130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R16-7-20260130","first-page":"384","article-title":"Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies","volume":"7","author":"Olyaei","year":"2001","journal-title":"Curr Opin Crit Care"},{"key":"R17-7-20260130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection.","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R18-7-20260130","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","article-title":"An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group","volume":"62","author":"Laskow","year":"1996","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-200803270-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:01:46Z","timestamp":1769778106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-200803270-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,27]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e318166927b","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3,27]]}}}